Recovery from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced immunosuppression in A/J mice by treatment with nonsteroidal anti- inflammatory drugs

Journal of the National Cancer Institute

Volumn 89, Issue 12, 1997, Pages 874-880

  Rioux, Nathalie ^a   Castonguay, Andre ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ACETYLSALICYLIC ACID; NAPROXEN; PROSTAGLANDIN E2; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CANCER RISK; CYTOPATHOGENIC EFFECT; DRUG EFFECT; FEMALE; IMMUNE DEFICIENCY; LUNG CANCER; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS INHIBITION; SMOKING;

EID: 0030923220     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.12.874     Document Type: Article

References (65)

1. Stanley K, Stjernsward J. Lung cancer - a worldwide health problem. Chest 1989;96(1 Suppl):1S-5S.
2. Castonguay A. Methods and strategies in lung cancer control. Cancer Res 1992;52(9 Suppl):2641s-2651s.
3. Anonymous. Anti-arthritic medication usage United States, 1991. Stat Bull Metrop Insur Co 1992;73:25-34.
4. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989;96(2 Pt 2 Suppl):647-55.
5. Aabakken L. Review article: non-steroidal anti-inflammatory drugs - the extending scope of gastrointestinal side effects. Aliment Pharmacol Ther 1992;6:143-62.
6. Arai I, Hamasaka Y, Futaki N, Takahashi S, Yoshikawa K, Higushi S, et al. Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res Commun Chem Pathol Pharmacol 1993;81:259-70.
7. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
8. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
9. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
10. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
11. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101:635-9.
12. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
13. Hixson LJ, Alberts DS, Krutzsch M, Einsphar J, Brendel K, Gross PH, et al. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994;3:433-8.
14. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
15. Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991; 126:1094-6.
16. Craven PA, DeRubertis FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonie carcinogenesis. Carcinogenesis 1992;13:541-6.
17. Rubio CA. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer 1986;58:1029-31.
18. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990;11:393-5.
19. Tanaka, T, Nishikawa A, Mori Y, Morishita M, Mori H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats [published erratum appears in Cancer Lett 1990;50:165]. Cancer Lett 1989;48:177-82.
20. McCormick DL, Wilson AM. Combination chemoprevention of rat mammary carcinogenesis by indomethacin and butylated hydroxytoluene. Cancer Res 1986;46:3907-11.
21. Carter CA, Ip MM, Ip C. A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7, 12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 1989; 10:1369-74.
22. Rao AR, Hussain SP. Modulation of methyl-cholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett 1988;43:15-9.
23. Cohen SM, Hasegawa R, Sakata T, Johansson SL. Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats. Cancer Res 1989;49:372-7.
24. Pepin P, Bouchard L, Nicole P, Castonguay A. Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis 1992;13:341-8.
25. Jalbert G, Castonguay A. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett 1992;66:21-8.
26. Duperron C, Castonguay A. Inhibition of lung tumorigenesis by aspirin in A/J mice. Carcinogenesis 1997;18:101-6.
27. 2 by tissue-fixed macrophages in colonic carcinoma. Digestion 1990;47:160-6.
28. Lala PK, Searloos MN. Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy, chapter 7. In: Harris JE, Braun DP, Anderson KM, editors. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton (FL): CRC Press, 1994.
29. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55:1464-72.
30. Flescher E, Fossum D, Gray PJ, Fernandes G, Harper MJ, Talal N. Aspirin-like drugs prime human T cells. Modulation of intracellular calcium concentrations. J Immunol 1991;146: 2553-9.
31. Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BW. Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma. Clin Immunol Immunopathol 1989;53:68-77.
32. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax 1987;42:241-9.
33. Gerrard JW, Heiner DC, Ko CG, Mink J, Meyer A, Dosman JA. Immunoglobulin levels in smokers and non-smokers. Ann Allergy 1980;44:261-2.
34. Srivastava ED, Barton JR, O'Mahony S, Phillips DI, Williams GT, Matthews N, et al. Smoking, humoral immunity, and ulcerative colitis. Gut 1991;32:1016-9.
35. US Department of Health and Human Services. Reducing the health consequences of smoking, 25 years of progress. Washington (DC): Office on Smoking and Health; 1989 Report No. DHHS Publ No. (CDC)89-8411, pp 43-55.
36. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988;9:875-84.
37. Hecht SS, Carmella SG, Foiles PG, Murphy SE, Peterson LA. Tobacco-specific nitrosamine adducts: studies in laboratory animals and humans. Environ Health Perspect 1993;99:57-63.
38. Hoffmann D, Brunnemann KD, Prokopczyk B, Djordjevic MV. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J Toxicol Environ Health 1994;41:1-52.
39. US Pharmacopeial Convention Inc., Drug information for the health care professional, Volume IA. Rockville (MD): 1990:462-512.
40. Sjogren HO, Hellstrom I. Production of polyoma specific transplantation antigenicity in Moloney leukemia cells. Exp Cell Res 1965;40:208-12.
41. Hudson L, Hay FC. Practical immunology. 3rd ed. Oxford: Blackwell Scientific, 1989:140-1.
42. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988; 15:61-9.
43. Powell WS. Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol 1982;86:467-77.
44. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholinesterase. Methods Enzymol 1990;187: 24-34.
45. Nair MP, Kronfol ZA, Schwartz SA. Effects of alcohol and nicotine on cytotoxic functions of human lymphocytes. Clin Immunol Immunopathol 1990;54:395-409.
46. Caggiula AR, McAllister CG, Epstein LH, Antelman SM, Knopf S, Saylor S, et al. Nicotine suppresses the proliferative response of peripheral blood lymphocytes in rats. Drug Dev Res 1992;26:473-9.
47. Hardin JA, Hinoshita F, Sherr DH. Mechanisms by which benzo[a]pyrene, an environmental carcinogen, suppresses B cell lymphopoiesis. Toxicol Appl Pharmacol 1992; 117:155-64.
48. Lindemann RA, Park NH. The effects of benzo[a]pyrene, nicotine, and tobacco-specific N-nitrosoamines on the generation of human lymphokine-activated killer cells. Arch Oral Biol 1989;34:283-7.
49. 1 mice by chronic exposure to ethanol in a liquid diet. Immunopharmacology 1993;26:31-51.
50. Desjardins R, Fournier M, Denizeau F, Krzystyniak K. Immunosuppression by chronic exposure to N-nitrosodimethylamine (NDMA) in mice. J Toxicol Environ Health 1992;37:351-61.
51. Holsapple MP, Tucker AN, NcNerney PJ, White KL Jr. Effects of N-nitrosodimethylamine on humoral immunity. J Pharmacol Exp Ther 1984;229:493-500.
52. Holsapple MP, Bick PH, Duke SS. Effects of N-nitrosodimethylamine on cell-mediated immunity. J Leukoc Biol 1985;37:367-81.
53. Seidel HJ, Kreja L. Effects of MNU on hematopoietic stem cells, the immune system and natural killer cells. J Cancer Res Clin Oncol 1990;108:214-20.
54. Hecht SS, Trushin N, Castonguay A, Rivenson A. Comparative tumorigenicity and DNA methylation in F344 rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N-nitrosodimethylamine. Cancer Res 1986; 46:498-502.
55. Castonguay A, Rioux N. Inhibition of lung tumorigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis 1997;18:491-6.
56. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-7.
57. Bilodeau JF, Wang M, Chung FL, Castonguay A. Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice. Free Radie Biol Med 1995;18:47-54.
58. Hall TJ, Chen SH, Brostoff J, Lydyard PM. Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol 1983;54:493-500.
59. Goto T, Herberman RB, Maluish A, Strong DM. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol 1983;130: 1350-5.
60. Futaki N, Takahashi S, Yokoyama M, Arai I, Higushi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-9.
61. Klein T, Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605-10.
62. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-10.
63. Boraschi D, Meltzer MS. Defective tumoricidal capacity of macrophages from A/J mice. I. Characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli. J Immunol 1979;122:1587-91.
64. Shimkin MB, Stoner GD. Lung tumors in mice: application to carcinogenesis bioassay. Adv Cancer Res 1975;21:1-58.
65. Piazza G, Rahm A, Pamukcu R, Ahnen D. Apoptosis fully accounts for the growth inhibitory activity of sulindac. Proc Am Assoc Cancer Res 1996;37:279.